To cite this paper use one of the standards below:
Pancreatic cancer is among the most lethal malignancies, often diagnosed at advanced stages due to non-specific early symptoms, leading to poor prognosis. Treatment options for late-stage disease remain limited in effectiveness. Chemotherapy commonly involves multi-drug regimens with significant adverse effects. Although immune checkpoint inhibitors have shown remarkable success in other cancers, their efficacy in pancreatic cancer is limited. A major reason is the immunosuppressive tumor microenvironment, largely driven by tumor-associated macrophages (TAMs), which suppress cytotoxic T-cell activity. One promising strategy is to block the CSF1/CSF-1R pathway, reducing TAMs presence and reprogramming their function to support T-cell activation. Small molecule inhibitors of CSF-1R have limited specificity, while monoclonal antibodies face cost and stability challenges. Computationally designed miniproteins offer high specificity, stability, and cost-effective production. Here, we designed de novo miniproteins targeting CSF-1R’s extracellular domain to enhance immunotherapy in pancreatic cancer.
Target structures were taken from the PDB. The Rosetta software suite, RifDock and ProteinMPNN neural network were used to generate initial backbones, dock and calculate the most probable sequence for the binders. Models with high experimental viability were selected based on structural predictions for complexes and monomers (binder) performed using AlphaFold-Multimer and AlphaFold2, respectively; folding simulations for top binders were also carried out using Rosetta. MD simulations of selected complexes and monomers were performed using the GROMACS package.
Here, 193 ligand models were selected at the end of the protocol. Their designed complex and monomers were similar to predictions and present high confidence, indicating increased probability of experimental success. We showcase one promising binder from the designed poll. MD simulations of the complex showed stability of interaction. Simulations of the binder free in solution also demonstrated structural stability.
The generated binders are potential biopharmaceuticals against CSF-1R. In-vitro studies are needed to assess efficacy. This approach is applicable to other pharmacological targets.
This work was supported by CNPq (465259/2014-6), CAPES, INCT-FCx, FAPESP (2014/50983-3) and LNCC computational resources.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper